Ginkgo Bioworks Holdings, Inc. (DNA) 株式分析

企業概要

Ginkgo Bioworks Holdings, Inc. is a biotechnology enterprise dedicated to the development of cell engineering platforms, specifically offering research and development solutions alongside specialized tools within the United States. The company operates primarily within the Healthcare sector and the Biotechnology industry, a domain characterized by high research expenditures and the pursuit of novel biological solutions for diverse applications. Its operational scale is defined by a market capitalization of $398.17M, an annual revenue of $170.16M, and a workforce comprising 485 employees. These financial figures indicate that the company functions as a mid-tier entity in its sector, possessing a significant but not dominant market presence relative to large-cap pharmaceutical peers. The valuation suggests the market is pricing the firm based on future technological potential rather than current profitability, given that the market cap exceeds the trailing twelve-month revenue by a factor of approximately 2.3 times. This structural positioning reflects the typical lifecycle of a biotechnology firm that prioritizes platform development and licensing over immediate profit generation.

財務健全性

The company reported a revenue of $170.16M over the trailing twelve months, yet it recorded a net income of $-312,763,008 and an EBITDA of $-267,822,000, revealing a substantial divergence between top-line activity and bottom-line profitability. This wide gap indicates a cost structure where operating expenses and research costs significantly outpace gross margins, resulting in a net loss that is nearly double the reported revenue. The free cash flow stands at $-72,883,000, which signifies a cash burn rate that limits the company's immediate financial flexibility and necessitates continuous capital raising or internal cash management to sustain operations. Margin analysis shows a gross margin of 72.4%, suggesting efficient production of cell engineering tools, but this is offset by an operating margin of -209.7% and a profit margin of -183.8%, highlighting severe operational inefficiencies relative to sales revenue. Regarding liquidity and leverage, the company holds $422.62M in cash against $439.88M in debt, resulting in a debt-to-equity ratio of 86.49, which points to a highly leveraged balance sheet where total liabilities exceed liquid assets. Despite the leverage, the current ratio of 4.92 suggests that short-term assets are more than four times the current liabilities, providing a buffer against immediate short-term solvency risks. Furthermore, the return on equity is -51.1% and the return on assets is -15.4%, metrics that reveal that management's capital deployment has resulted in value destruction rather than capital appreciation for shareholders during the reporting period.

バリュエーション評価

Valuation metrics for Ginkgo Bioworks include a trailing P/E ratio of N/A and a forward P/E of -1.77, implying that the market is currently unable to value the stock based on historical earnings and is instead anticipating a path toward future profitability to establish a meaningful multiple. The price-to-book ratio is 0.74, indicating that the stock trades at a discount to its book value, a common characteristic for unprofitable growth firms where the market discounts assets due to the risk of obsolescence or impairment. Alternative valuation measures such as the price-to-sales ratio of 2.34 and an EV/EBITDA of -1.46 suggest that investors are pricing the company primarily on its revenue generation capabilities and potential platform value rather than earnings power. Price action over the last year has seen the stock fluctuate between a 52-week high of $17.58 and a 52-week low of $5.37, meaning the current share price sits significantly below the yearly peak and reflects the high volatility inherent in the biotechnology sector. The beta value of 1.57 indicates that the stock's price volatility is approximately 57% higher than that of the broader market, signaling that price swings will likely be amplified during periods of general market movement. These metrics collectively portray a high-risk, high-volatility asset class where valuation is detached from traditional earnings-based fundamentals.

Growth & Income

The company experienced a revenue growth rate of -23.8% year-over-year, while earnings growth is N/A due to the absence of positive earnings; this contraction in revenue suggests that the business is currently facing headwinds in securing contracts or maintaining market share within its cell engineering segments. The absence of positive earnings growth reinforces the observation that the company is not in an expansion phase regarding profitability, but rather in a phase of revenue contraction which often precedes a strategic pivot or restructuring. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute cash to shareholders and instead retains all available capital to fund its high-cost research and development activities. This reinvestment strategy is typical for biotechnology firms that require substantial cash reserves to continue their operations and pursue long-term technological breakthroughs before achieving commercial viability. The overall growth and income profile is characterized by negative revenue momentum, a complete lack of dividend income, and a reliance on external capital markets to fund operations given the negative free cash flow and significant debt obligations.